<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Formycon Ag — News on 6ix</title>
<link>https://6ix.com/company/formycon-ag</link>
<description>Latest news and press releases for Formycon Ag on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 09 Dec 2025 12:18:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/formycon-ag" rel="self" type="application/rss+xml" />
<item>
<title>Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada</title>
<link>https://6ix.com/company/formycon-ag/news/formycon-and-zydus-partner-for-exclusive-licensing-and-supply-agreement-of-fyb206-a-biosimilar-to-keytrudar-pembrolizumab-in-the-us-and-canada</link>
<guid isPermaLink="true">https://6ix.com/company/formycon-ag/news/formycon-and-zydus-partner-for-exclusive-licensing-and-supply-agreement-of-fyb206-a-biosimilar-to-keytrudar-pembrolizumab-in-the-us-and-canada</guid>
<pubDate>Tue, 09 Dec 2025 12:18:00 GMT</pubDate>
<description>Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for a successful launch of FYB206Strong early partnering interest underscores industry confidence in Formycon’s biosimilar expertise and development excellenceAgreement structure includes in total mid-teens-million-euro upfront and 2025 milestone payments, alongside additional development and regulatory milestones and a mid-double-digit-gross-profit-share</description>
</item>
<item>
<title>Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region</title>
<link>https://6ix.com/company/formycon-ag/news/formycon-and-ms-pharma-sign-exclusive-commercialization-partnership-for-keytrudar-biosimilar-candidate-fyb206-for-the-mena-region</link>
<guid isPermaLink="true">https://6ix.com/company/formycon-ag/news/formycon-and-ms-pharma-sign-exclusive-commercialization-partnership-for-keytrudar-biosimilar-candidate-fyb206-for-the-mena-region</guid>
<pubDate>Thu, 04 Dec 2025 09:14:00 GMT</pubDate>
<description>Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into an exclusive licensing and supply agreement for the commercialization of FYB206, Formycon's biosimilar candidate to the blockbuster drug Keytruda®[1] (pembrolizumab), in the Middle East and North Africa ("MENA region"). The agreement includes an option for future technology transfer.</description>
</item>
<item>
<title>Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar</title>
<link>https://6ix.com/company/formycon-ag/news/polpharma-biologics-announces-commercial-launch-of-europes-first-pre-filled-syringe-presentation-of-a-ranibizumab-biosimilar</link>
<guid isPermaLink="true">https://6ix.com/company/formycon-ag/news/polpharma-biologics-announces-commercial-launch-of-europes-first-pre-filled-syringe-presentation-of-a-ranibizumab-biosimilar</guid>
<pubDate>Tue, 21 Oct 2025 08:51:00 GMT</pubDate>
<description>ZURICH, October 21, 2025--Polpharma Biologics today announced Ranivisio® PFS (ranibizumab biosimilar pre-filled syringe), is now commercially available in France.</description>
</item>
<item>
<title>Formycon Invites to Conference Call on 2025 Half-year Results and Announces Participation in International Investor Conferences in the 3rd Quarter of 2025</title>
<link>https://6ix.com/company/formycon-ag/news/formycon-invites-to-conference-call-on-2025-half-year-results-and-announces-participation-in-international-investor-conferences-in-the-3rd-quarter-of-2025</link>
<guid isPermaLink="true">https://6ix.com/company/formycon-ag/news/formycon-invites-to-conference-call-on-2025-half-year-results-and-announces-participation-in-international-investor-conferences-in-the-3rd-quarter-of-2025</guid>
<pubDate>Wed, 30 Jul 2025 21:21:23 GMT</pubDate>
<description>PLANEGG-MARTINSRIED, Germany - July 30, 2025 (NEWMEDIAWIRE) - Formycon AG (FSB: FYB, Prime Standard, Formycon") plans to publish its results of the first half of the 2025 fiscal year on August 13, 2025. The Management Board will discuss the compa...</description>
</item>
<item>
<title>Formycon Successfully Completes Patient Enrollment for the Clinical Development of Its Keytruda(R) Biosimilar Candidate FYB206</title>
<link>https://6ix.com/company/formycon-ag/news/formycon-successfully-completes-patient-enrollment-for-the-clinical-development-of-its-keytrudar-biosimilar-candidate-fyb206</link>
<guid isPermaLink="true">https://6ix.com/company/formycon-ag/news/formycon-successfully-completes-patient-enrollment-for-the-clinical-development-of-its-keytrudar-biosimilar-candidate-fyb206</guid>
<pubDate>Thu, 10 Jul 2025 21:40:10 GMT</pubDate>
<description>Streamlined clinical development program, which no longer requires a Phase III trial, is already in a far advanced stage Last patient enrolled in Dahlia pharmacokinetic (PK) study (Last Patient-In) First patients have completed all 17 treatment ...</description>
</item>
<item>
<title>Ordinary Annual General Meeting of Formycon AG Approves all Proposed Resolutions by Large Majorities</title>
<link>https://6ix.com/company/formycon-ag/news/ordinary-annual-general-meeting-of-formycon-ag-approves-all-proposed-resolutions-by-large-majorities</link>
<guid isPermaLink="true">https://6ix.com/company/formycon-ag/news/ordinary-annual-general-meeting-of-formycon-ag-approves-all-proposed-resolutions-by-large-majorities</guid>
<pubDate>Wed, 18 Jun 2025 20:21:04 GMT</pubDate>
<description>Management provides detailed report on financial year 2024 and provides outlook for 2025 Supervisory Board expands to six members; Klaus Rhrig re-elected Dr. Graham Keith Dixon elected as a new member of the Supervisory Board PLANEGG-MARTINSRIE...</description>
</item>
<item>
<title>Fresenius Kabi to announce the commercial launch of Otulfi™*, an approved Ustekinumab Biosimilar in Canada</title>
<link>https://6ix.com/company/formycon-ag/news/fresenius-kabi-to-announce-the-commercial-launch-of-otulfitm-an-approved-ustekinumab-biosimilar-in-canada</link>
<guid isPermaLink="true">https://6ix.com/company/formycon-ag/news/fresenius-kabi-to-announce-the-commercial-launch-of-otulfitm-an-approved-ustekinumab-biosimilar-in-canada</guid>
<pubDate>Tue, 27 May 2025 12:30:00 GMT</pubDate>
<description>Fresenius Kabi Canada announces that its ustekinumab biosimilar, developed by Formycon AG, is now commercially available in Canada. Otulfi™ is indicated for the treatment of several serious inflammatory diseases and benefiting more patients with autoimmune conditions. It is the third Fresenius Kabi immunology biosimilar approved in Canada for the treatment of Gastroenterology, Dermatology or Rheumatology conditions, providing treatment flexibility to manage patients at different stages of their</description>
</item>
</channel>
</rss>